Simple and robust approach for breast cancer risk assessment is an innovative approach designed for all healthy women, regardless of ethnicity, particularly those not at increased risk of carrying a BRCA gene mutation.
This solution provides physicians with a more precise estimation of breast cancer risk and supports personalized screening plans.
is a an extremely robust approach, based on over a decade of research and hundreds of thousands of subjects.
Estrogens are natural hormones that are important in sexual development. It also regulates a woman’s menstrual cycle and affects the entire reproductive system. During the period If the woman's egg is not fertilized, estrogen levels decrease sharply, and menstruation begins. If the egg is fertilized, estrogen works with progesterone, another hormone, to stop ovulation during pregnancy. Family history is one of the inevitable genetic risk factors for the development of breast cancer. Ongoing research is helping to identify the genes responsible for this increased hereditary risk. Mutations in the BRCA1 and BRCA2 gene are currently the most known and discussed genetic risk factors, but new genetic links are being discovered regularly.
Most cases of breast cancers (around 80 90%) are the result of both genes and lifestyles factors. Rare high-risk mutations particularly in the BRCA1 and BRCA2 genes explain less than 10% of breast cancers and account for a small proportion of breast cancer cases in the general population. Over recent years many new genetic risk factors have been discovered in so-called genome-wide association studies (GWAS) – these are multiple common, low-risk variants (single nucleotide polymorphisms [SNPs]) associated with breast cancer.
We have looked at a panel of 70 SNPs to calculate genetic "risk" – this is not the absolute risk of breast cancer because the overall risk depends on genes and lifestyles factors together. Our patients must know that besides the genetic risk, the figure can be reduced with an appropriate lifestyle i.e., genetic risk is not fixed.
The study of the relationship between genes and response to drugs has been the subject of intensive research over the past two decades. Robust evidence now exists to support testing under clinical conditions.
Pharmacogenomics testing is the most recent addition to the NGR portfolio. We analyse genotypes associated with drug responsiveness for cardiovascular disease, psychiatry and pain management, amongst others. Reports provide practitioners with detailed guidelines on gene-drug interactions; highlighting potential side effects, increased toxicity, and lack of efficacy